MYOSITIS

This study is testing whether adding a new type of immune cell therapy (called AlloNK) to an existing drug (rituximab) can better control several autoimmune diseases that have come back after standard treatments. The trial will enroll 90 adults with rheumatoid arthritis, Sjögren'…

This Phase 3 study is testing whether the investigational drug dazukibart can help control symptoms of dermatomyositis and polymyositis—rare autoimmune diseases that cause painful muscle inflammation and weakness. The trial will enroll 318 adults who are already taking standard m…

This early-stage study is testing a new treatment called CTX112 for adults with severe autoimmune diseases like lupus, scleroderma, and inflammatory muscle disease that haven't responded to standard therapies. The treatment uses genetically modified immune cells from healthy dono…

This study aims to understand whether certain environmental exposures—like infections, chemicals, or stressful events—might trigger autoimmune muscle diseases called myositis. Researchers will compare 580 people with myositis to healthy volunteers, collecting blood, dust samples,…

This study aims to understand what research matters most to people living with rare muscle diseases called myositis. Researchers will collect perspectives from 700 patients and caregivers worldwide through online surveys and discussions. The goal is to create a list of patient-pr…

This study aims to create a large collection of blood samples and health information from people with autoimmune diseases like lupus and scleroderma. Researchers will use these samples to look for new biological markers that could help diagnose diseases earlier, predict how they …